

In the Claims:

22 3. (Amended) A compound according to claim 2 wherein R² is aryl, Het¹, C₃₋₇cycloalkyl, or C₁₋₆alkyl substituted with one or two substituents selected from hydroxy, cyano, amino, mono- or di(C₁₋₄alkyl)amino, C₁₋₆alkyloxy, C₁₋₆alkylsulfonyloxy, C₁₋₆alkyloxycarbonyl, C₃₋₇cycloalkyl, aryl, aryloxy, arylthio, Het¹, Het¹oxy and Het¹thio; and if X is O, S or NR³, then R² may also represent aminocarbonyl, aminothiocarbonyl, C₁₋₄alkylcarbonyl, C₁₋₄alkylthiocarbonyl, arylcarbonyl or arylthiocarbonyl.

4. (Amended) A compound according to claim 3 wherein the 6-azauracil moiety is in the para position relative to the central carbon atom.

13 5. (Amended) A compound according to claim 4 wherein q is 1 or 2 and one R⁴ substituent is in the 4 position; and p is 1 or 2 and the one or two R⁵ substituents are in the ortho position relative to the central carbon atom.

6. (Amended) A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 1.

7. (Amended) A process for preparing a composition as claimed in claim 6, wherein a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound as defined in claim 1.

✓ Cancel Claims 8 and 9 without prejudice and add new Claims 13 and 14 as follows.

14. (New) The method of Claim 13, wherein the eosinophil-dependent inflammatory disease is selected from bronchial asthma, atopic dermatitis, allergic rhinitis or allergic conjunctivitis.

[illegible]